Method and device for minimally invasive site specific ocular drug delivery

• US 20080027371A1
• Filed: 07/26/2007
• Published: 01/31/2008
• Est. Priority Date: 07/26/2006
• Status: Abandoned Application

• Current Assignee: Aciont, Inc.
• Original Assignee: Aciont, Inc.
• Inventors: Higuchi, John W., Tuitupou, Anthony L.
• Application Number:
  US11/881,729
• Publication Number:
  US 20080027371A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

The present invention includes techniques for delivering an active agent into the eye of a subject. Accordingly, in one aspect a method may include delivering invasively an active agent into a peripheral tissue of the eye to form a drug reservoir, and applying an electric current to the drug reservoir to thus drive at least a portion of the active agent at least partially through the choroid. Numerous configurations are contemplated for the positioning of the electric current relative to the drug reservoir. For example, in one aspect the electric current may be applied to the drug reservoir from a non-invasively positioned electrode. In another aspect, the electric current may be applied to the drug reservoir from an invasively positioned electrode. A variety of invasive positions are contemplated, including, for example, positioning the invasive electrode within the peripheral tissue. In yet another aspect, delivering the active agent may further include implanting an invasive electrode having an associated drug reservoir containing the active agent into the peripheral tissue.

Claims

1. A method of delivering an active agent into an eye of a subject, comprising:

delivering invasively an active agent into a peripheral tissue of the eye to form a drug reservoir; and

applying an electric current to the drug reservoir to thus drive at least a portion of the active agent at least partially through the choroid.

2. The method of claim 1, wherein the electric current is applied to the drug reservoir from a non-invasively positioned electrode.

3. The method of claim 2, further comprising completing an electrical circuit with the non-invasive electrode via a non-invasive return electrode positioned on an eye surface.

4. The method of claim 1, wherein the electric current is applied to the drug reservoir from an invasively positioned electrode.

5. The method of claim 4, wherein the invasive electrode is located within the peripheral tissue.

6. The method of claim 4, wherein delivering the active agent further includes implanting an invasive electrode having an associated drug reservoir containing the active agent into the peripheral tissue.

7. The method of claim 4, further comprising completing an electrical circuit with the invasive electrode via a return electrode positioned within the peripheral tissue.

8. The method of claim 7, further comprising iontophoretically delivering a secondary agent from a secondary reservoir associated with the return electrode into the eye of the subject.

9. The method of claim 8, wherein the secondary agent is a depot forming agent.

10. The method of claim 1, further comprising allowing the active agent to diffuse along the peripheral tissue prior to applying the electrical current.

11. The method of claim 1, wherein the active agent is selected from the group consisting of hydromorphone, dexamethasone, dexamethasone phosphate, amikacin, oligonucleotides, F_ab peptides, PEG-oligonucleotides, salicylate, tropicamide, methotrexate, 5-fluorouracil, squalamine, triamcinolone acetonide, triamcinolone acetonide phosphate, diclofenac, combretastatin A4, mycophenolate mofetil, mycophenolic acid, bevacizumab, ranibizumab, and prodrugs and combinations thereof.

12. The method of claim 11, wherein the active agent is triamcinolone acetonide phosphate.

13. The method of claim 11, wherein the active agent is dexamethasone phosphate.

14. The method of claim 1, further comprising delivering a secondary agent to the eye of the subject.

15. The method of claim 14, wherein the secondary agent is invasively delivered with the drug reservoir.

16. The method of claim 14, wherein the secondary agent is non-invasively delivered with the electric current.

17. The method of claim 14, wherein the secondary agent is a member selected from the group consisting of depot forming agents, active agents, vasoconstrictor agents, solubility modifying agents, and combinations thereof.

18. The method of claim 14, wherein the secondary agent is a vasoconstrictor agent.

19. The method of claim 18, wherein the vasoconstrictor agent is a member selected from the group consisting of naphazoline, tetrahydrozoline, phenylethylamine, epinephrine, norepinephrine, dopamine, dobutamine, colterol, ethylnorepinephrine, isoproterenol, isoetharine, metaproterenol, terbutaline, metearaminol, phenylephrine, tyramine, hydroxyamphetamine, ritrodrine, prenalterol, methoxyamine, oxymetazoline, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, methentermine, phentermine, fenfluramine, propylhexedrine, diethylpropion, phenmetrazine, phendimetrazine, and combinations thereof.

20. The method of claim 19, wherein the vasoconstrictor agent is oxymetazoline.

21. The method of claim 17, wherein the secondary agent is a depot forming agent.

22. A method of forming a sustained release drug depot at or near a posterior pole of an eye of a subject, comprising:

delivering invasively an active agent into a peripheral tissue of the eye to form a drug reservoir at a first delivery site;

delivering a depot forming agent into a peripheral tissue of the eye to form a depot forming agent reservoir at a second delivery site, wherein the first delivery site and the second delivery site are spatially distinct; and

allowing the active agent and the depot forming agent to diffuse to an intermediate location between the first site and the second site to form a drug depot.

23. The method of claim 22, wherein the active agent is water soluble.

24. The method of claim 22, wherein the intermediate location is in the posterior pole of the eye.